Core Viewpoint - Investors are evaluating which stock between Avantor, Inc. (AVTR) and Alignment Healthcare (ALHC) offers better value for investment at the current time [1] Group 1: Zacks Rank and Earnings Outlook - AVTR has a Zacks Rank of 2 (Buy), while ALHC has a Zacks Rank of 3 (Hold), indicating a more favorable earnings outlook for AVTR [3] - The Zacks Rank system emphasizes companies with positive earnings estimate revisions, suggesting that AVTR's earnings outlook is improving more significantly than ALHC's [3] Group 2: Valuation Metrics - AVTR has a forward P/E ratio of 12.47, significantly lower than ALHC's forward P/E of 213.30, indicating that AVTR may be undervalued [5] - The PEG ratio for AVTR is 3.86, while ALHC's PEG ratio is 5.62, further suggesting that AVTR offers better value considering expected earnings growth [5] - AVTR's P/B ratio is 1.36 compared to ALHC's P/B of 26.37, reinforcing the notion that AVTR is more attractively priced relative to its book value [6] Group 3: Value Grades - Based on the aforementioned valuation metrics, AVTR has earned a Value grade of A, while ALHC has a Value grade of C, indicating a stronger value proposition for AVTR [6][7]

ORANGE, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC), will release its fourth quarter and full-year 2025 financial results on Thursday, Feb. 26, 2026, after market close. Following the release, the company will host a conference call to review its financial results at 5 p.m. EST. Conference Call DetailsA live audio webcast will be available online at https://ir.alignmenthealth.com/. At the start of the conference call, participants may access the webcast at the followi ...

We recently published 10 Big Names With Painful Declines. Alignment Healthcare Inc. (NASDAQ:ALHC) was one of the worst performers on Tuesday. Alignment Healthcare fell by 11.97 percent on Tuesday to close at $20.96 apiece as investors unloaded positions in listed insurers following the lower-than-expected preliminary payment proposals for the Medicare Advantage program. According to the Centers for Medicare and Medicaid Services (CMS), net average payment is projected to increase by only 0.09 percent, f ...

Several healthcare and biotech stocks posted solid gains in Tuesday's after-hours session, with most moves occurring without company-specific news.Acumen Pharmaceuticals, Inc. (ABOS) advanced 8.09% to close at $2.94 after hours, adding $0.22 to its share price.Fulgent Genetics, Inc. (FLGT) rose 5.98% to $28.90 as of 6:59 p.m. EST, gaining $1.63 in extended trading.Fractyl Health, Inc. (GUTS) climbed 5.19% to $2.23, up $0.11 after hours.Coeptis Therapeutics Holdings, Inc. (COEP) added 4.14% to finish at $13 ...

分组1 - UnitedHealth Group's Q4 revenue and full-year revenue outlook fell short of Wall Street forecasts, leading to a nearly 20% drop in its stock price and impacting the broader managed care sector [2][3] - The Trump administration proposed nearly flat reimbursement rates for Medicare Advantage payers in 2027, with an average payment increase of only 0.09%, significantly lower than the expected 4%-6% rise [3] - UnitedHealth reported adjusted EPS of $2.10 for the quarter, meeting consensus, but Q4 revenue of $113.2 billion missed forecasts by approximately $520 million despite a 12% year-over-year growth [4] 分组2 - For 2026, UnitedHealth projects adjusted EPS of over $17.75, aligning closely with analyst expectations, but its revenue forecast of more than $439 billion is below the Street's consensus of $456 billion [4] - Analysts have described the current situation for UnitedHealth as a "somewhat disastrous start" to the year, following a challenging 2025 where shares declined by about 30% [5]

Lahiru Lakmal/iStock via Getty Images Leading publicly traded US managed care insurers are expected to report both sequential and year-over-year declines in net income for the fourth quarter of 2025. All eight of the largest publicly traded managed care ...

Green stock chart rising beside medical caduceus and DNA icons, signaling Medicare Advantage rally for ALHC. Key Points Alignment Healthcare stock is up more than 400% since April 2024, as improving Medicare Advantage cost trends and disciplined growth have driven a fundamental re-rating. ALHC’s value-based care model positions the company to benefit from a Medicare rebound as hospital economics stabilize and utilization normalizes into 2026. While ALHC stock remains technically overextended, the bulli ...

Alignment Healthcare Inc. (NASDAQ:ALHC) is one of the best mid-cap growth stocks to buy right now. On January 14, UBS raised its price target on Alignment Healthcare to $21 from $18, while maintaining a Neutral rating. On January 6, Piper Sandler analyst Jessica Tassan raised the firm’s price target for Alignment Healthcare Inc. (NASDAQ:ALHC) from $20 to $30 and maintained an Overweight rating. The firm updated its financial model to account for strong Annual Enrollment Period/AEP sales and retention leve ...

Core Insights - Alignment Healthcare (ALHC) reached a new 52-week high of $23.30, reflecting strong membership growth and reaffirmed guidance, making it a stock worth monitoring [1][2][9] Company Overview - Alignment Healthcare is a Medicare Advantage company based in California, focusing on redefining senior care through partnerships with local providers to deliver coordinated, high-quality, and low-cost care [4] - The company emphasizes a customized care model, a 24/7 concierge care team, and its proprietary platform, AVA, aimed at empowering seniors [4] Membership Growth - As of January 1, Alignment reported a plan membership of approximately 275,300, representing a 31% year-over-year growth [5] - Since its IPO in 2021, the company has achieved a compounded annual membership growth rate of about 30% in the Medicare Advantage market [5] Future Projections - Alignment anticipates health plan membership to reach between 290,000 and 296,000 by year-end 2026, indicating a growth of about 24% to 27% compared to its 2025 guidance midpoint [6] - The company expects a consensus-adjusted EBITDA of around $145 million for 2026, consistent with its full-year guidance [6] Leadership and Innovation - CEO John Kao highlighted the company's commitment to seniors, stating that strong performance is derived from delivering better care, outcomes, and lower costs [7] - The company announced the appointment of Adnan Mansour as Chief Digital Officer to unify technology and information functions, focusing on expanding the impact of its AI-powered AVA platform [8] Performance Metrics - The stock traded at a volume of 2,359,659 shares, slightly below the average of 2,669,030, with a market capitalization of $4.662 billion [3] - In after-hours trading, the stock increased to $23.50, up $0.20 or 0.86% [3] Quality of Care - 100% of members enrolled in plans were rated 4 stars or higher by the Centers for Medicare & Medicaid Services for the second consecutive year, indicating high-quality outcomes [7]

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal! AI is eating the world—and the machines behind it are ravenous. Each ChatGPT query, each model update, each robotic breakthrough consumes massive amounts of energy. In fact, AI is already pushing global power grids to the brink. Wall Street is pouring hundreds of billions into artificial intelligence—training smarter chatbots, automating industries, and b ...